As part of its mission and since its inception, DNDi has advocated for increased public responsibility and a more enabling environment for neglected disease R&D.
May 10-11, 2017
Amsterdam, The Netherlands
Organized by the World Health Organization in collaboration with the Dutch Ministry of Health, the Fair Pricing Forum was held to discuss options for a fairer pricing system, that is sustainable for both health systems and innovation challenges to access and how to move forward.
DNDi participated in the event.
[21 September, 2016]
The Drugs for Neglected Diseases initiative (DNDi) welcomes the commitment made by world leaders today at the United Nations (UN) General Assembly to address one of the world’s most pressing public health issues, antimicrobial resistance (AMR).
[14 September, 2016]
The Drugs for Neglected Diseases initiative (DNDi) today welcomes the release of the report of the United Nations Secretary General’s High-Level Panel on Access to Medicines. The Panel has clearly confirmed the policy misalignment between intellectual property and trade rules, international human rights obligations, and public health objectives. It has underlined many immediate access challenges and steps that must be taken to overcome them, and highlighted that existing funding and incentive mechanisms are not adequate to stimulate innovation to address global public health needs.
[6 June, 2016]
The Access to Medicine Foundation report explores the progress made by major pharmaceutical companies in collaborating to innovate products for diseases of poverty, and the success of research & development (R&D) models in incentivizing these contributions. For the past 10 years, the Access to Medicine Foundation has tracked the progress of pharmaceutical engagement in R&D for neglected diseases, they found that models like Product Development Partnerships (PDPs) have been highly successful in creating incentives for pharmaceutical companies to participate in access-friendly R&D.
[27 May, 2016]
At the 69th WHA, Member States were asked to consider the outcomes of the Open-Ended Meeting and continue discussions on issues related to monitoring, coordination and financing for health research. Michelle Childs, DNDi‘s Head of Policy Advocacy, delivered the following statement on behalf of DNDi.
[2 May, 2016]
A DNDi Intervention was presented by Bernard Pécoul at this open-ended meeting by Member States on CEWG.
[27 February, 2016]
The proposed objective of the UN Secretary General’s High-Level Panel on Access to Medicines is to review and assess proposals and recommend solutions for remedying the policy incoherence between the rights of inventors, international human rights law, trade rules and public health in the context of health technologies. DNDi submitted a formal contribution.
[23 February, 2016]
DNDi attended the 138th Executive Board of the World Health Organization. The Executive Board was considering a resolution to add the mycetoma to WHO’s official list of neglected diseases.The mycetoma resolution will be proposed for adoption at the upcoming World Health Assembly agenda in May.
[22 May, 2015]
Alexandra Heumber, DNDi‘s Head of Policy Affairs, delivered a statement on behalf of DNDi at the 68th World Health Assembly (WHA).
A new paper recently commissioned by DNDi examines the possibilities of creating a pooled international R&D fund for the Demonstration Projects that were selected as part of the process following on the report of the WHO Consultative Expert Working Group on Research and Development (CEWG): “Demonstration Financing: Considerations for a Pilot Pooled International Fund for R&D.”
To mark its 10 year anniversary, DNDi has issued a report that explores the lessons learned from a decade of research and development (R&D) of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model.
[11 December, 2013]
This year’s G-FINDER Report, providing a survey of global investment into research and development (R&D) of new products for neglected diseases, gives some key information for the year 2012.
[3-4 December, 2013]
WHO Member States from every regions are currently going through a selection process of “demonstration projects” in order to provide evidences on innovative mechanisms to fund and coordinate public health R&D to address unmet medical needs of developing countries and to contribute to further discussion on a sustainable global framework as recommended by the Expert Working Group on Financing and Coordination (CEWG). DNDi has been involved in the overall CEWG process.
[4 June, 2013]
On the occasion of its 10th anniversary, DNDi and founding partner KEMRI brought together key African decision makers and public health actors to explore the challenges for research and development in Africa. The first day focused on regulatory harmonization with a view to accelerating access to essential medicines and vaccines in Africa. This resulting document examines the progress made to date, in anticipation of further discussions.
[13-14 December, 2012]
At an international event in New York on 13 and 14 December 2012 organized by DNDi and MSF, ‘Lives in the Balance’, a group of the key actors in the field of Chagas disease – from R&D to treatment access and prevention – announced their plans to join forces to address the needs of Chagas disease patients. The ‘Global Chagas Disease Coalition’ calls for increased collaboration to change the course of this disease that affects millions throughout Latin America and beyond.
[3 December, 2012]
This year’s G-FINDER Report provides a survey of global investment into research and development (R&D) of new products for neglected diseases in 2011. Read a comment by Bernard Pécoul on the report’s findings.
In Europe, DNDi works together with partners from civil society and seven other PDPs in order to advocate also for more leadership of the European Union (EU) in addressing research gaps for poverty-related and neglected diseases. The new upcoming EU Framework for Research and Innovation “Horizon 2020” and the continuation of a revised EDCTP programme will be a unique opportunity to demonstrate active leadership in the area of product-oriented and patient driven world-class research. The two position papers suggest to policy leaders, how this can be done.
DNDi has issued a policy brief: concerning the CEWG report: ‘Transforming Individual Successes into Sustainable Change to Ensure Health Innovation for Neglected Patients: Why an Essential Health R&D Convention Is Needed’.
DNDi’s 4th Partners’ meeting took place this year in Rio de Janeiro, Brazil, on December 2nd. DNDi’s progress in bringing new treatments to neglected patients was reviewed and the main challenges in access to new tools were evaluated, resulting in a Call to Action. More than 260 participants including international health researchers, policy makers, and experts from around the world participated.
DNDi is itself an example of a new form of international collaboration in health R&D that has successfully attracted new public and private funding to this field. Both to influence discussions on R&D financing at the WHO and in other fora and to support its own long-term funding strategy, in 2011, DNDi conducted an evaluation on existing and proposed R&D incentives and funding mechanisms, and developed an Outlook piece on the topic.